Developing innovative drugs for the treatment of liver diseases

Learn more about Tiziana

Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes

01 July 2019

Independent Third Party Article in New England Journal of Medicine reports on Intravenous Treatment with a Humanized Anti-CD3 mAb showing delays in progression of Type 1 Diabetes; Findings may have the potential to expand therapeutic benefits of Tiziana’s Foralumab, the...

Read more

Change of Adviser

28 June 2019

Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, announces the appointment of Shore Capital Stockbrokers Limited as...

Read more

PDMR dealings

25 June 2019

New York/London, 25 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 24 June 2019, Panetta Partners...

Read more

Our Mission

Our mission is to bring breakthrough therapies to patients with the aim of reversing severe liver diseases, autoimmune and inflammatory diseases and optimizing health outcomes.

Learn more

Clinical Candidates

With several candidates in the clinic, our development portfolio is supported by extensive IP and a strong pipline of in-licenced clinical and pre-clinical assets.

Clinical development pipeline

Milciclib

Milciclib is the Company’s Phase 2 clinical candidate for the treatment of multiple cancer indications such as hepatocellular carcinoma, thymic cancer and thymoma.

Learn more about Milciclib

Foralumab

Foralumab is a fully human anti-CD3 monoclonal antibody (mAb) for treatment of NASH, Crohn’ s Disease and a neurodegenerative indication.

Learn more about Foralumab

Pre-Clinical Candidates

With several candidates being prepared for clinic, our development portfolio is supported by extensive IP and a strong pipline of in-licenced clinical and pre-clinical assets.

Anti IL-6r (TZLS-501)

We are developing a fully human monoclonal antibody (mAb) targeting the receptor for IL-6. This asset was in-licensed from Novimmune in January 2017.

Learn more about Anti IL-6r

StemPrintER™

StemPrintER is a multi-gene signature assay intended for use as a diagnostic screen in patients with estrogen-receptor positive ER+/HER2 negative breast cancers.

Learn more about StemPrintER™

Clinical Trials

Tiziana is currently conducting clinical development programs for Foralumab and Milciclib

Milciclib

We initiated a Phase 2a trial (CDKO-125a-010) of Milciclib safety and tolerability as a single therapy in sorafenib-resistant patients with HCC in the first half of 2017.

See more Milciclib clinical trials

Foralumab

Tiziana is currently conducting a Phase I clinical trial of nasally-dosed Foralumab in healthy subjects in collaboration with Dr. Howard Weiner at Brigham and Women’s Hospital in Boston.

See more Foralumab clinical trials

Tiziana Life Sciences is listed on NASDAQ and AIM